Nintedanib in children and adolescents with fibrosing interstitial lung disease: the InPedILD trial

被引：0
|
作者：
Matthias, Griese [1 ]
Robin, Deterding [2 ,3 ]
Lisa, Young R. [4 ]
Emily, DeBoer M. [2 ,3 ]
David, Warburton [5 ,6 ]
Steven, Cunningham [7 ]
Nicolaus, Schwerk [8 ]
Kevin, Flaherty R. [9 ]
Kevin, Brown K. [10 ]
Mihaela, Dumistracel [11 ]
Elvira, Erhardt [12 ]
Julia, Bertulis [12 ]
Martina, Gahlemann [13 ]
Susanne, Stowasser [14 ]
机构：
[1] Ludwig Maximilians Univ Munchen, Hauner Childrens Hosp, German Ctr Lung Res DZL, Munich, Germany
[2] Univ Colorado Denver, Sect Pediat Pulm & Sleep Med, Dept Pediat, Denver, CO USA
[3] Childrens Hosp Colorado, Aurora, CO USA
[4] Childrens Hosp Philadelphia, Div Pulm & Sleep Med, Philadelphia, PA USA
[5] Childrens Hosp Los Angeles, Los Angeles, CA USA
[6] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA
[7] Univ Edinburgh, Ctr Inflammat Res, Edinburgh, Midlothian, Scotland
[8] Hannover Med Sch, Clin Pediat Pulmonol Allergol & Neonatol, Hannover, Germany
[9] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA
[10] Natl Jewish Hlth, Dept Med, Denver, CO USA
[11] Boehringer Ingelheim Pharma GmbH Co KG, Ingelheim, Germany
[12] Boehringer Ingelheim Pharma GmbH Co KG, Biberach, Germany
[13] Boehringer Ingelheim Schweiz GmbH, Basel, Switzerland
[14] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
来源：
KLINISCHE PADIATRIE | 2023年 / 235卷 / 02期
关键词：
D O I：
10.1055/s-0043-1761556
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
P46
引用
收藏
页码：125 / 125
页数：1
相关论文
共 50 条
  • [21] Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK
    Dixon, Giles
    Hague, Samuel
    Mulholland, Sarah
    Adamali, Huzaifa
    Khin, Aye Myat Noe
    Thould, Hannah
    Connon, Roisin
    Minnis, Paul
    Murtagh, Eoin
    Khan, Fasihul
    Toor, Sameen
    Lawrence, Alexandra
    Naqvi, Marium
    West, Alex
    Coker, Robina K.
    Ward, Katie
    Yazbeck, Leda
    Hart, Simon
    Garfoot, Theresa
    Newman, Kate
    Rivera-Ortega, Pilar
    Stranks, Lachlan
    Beirne, Paul
    Bradley, Jessica
    Rowan, Catherine
    Agnew, Sarah
    Ahmad, Mahin
    Spencer, Lisa G.
    Aigbirior, Joshua
    Fahim, Ahmed
    Wilson, Andrew M.
    Butcher, Elizabeth
    Chong, Sy Giin
    Saini, Gauri
    Zulfikar, Sabrina
    Chua, Felix
    George, Peter M.
    Kokosi, Maria
    Kouranos, Vasileios
    Molyneaux, Philip
    Renzoni, Elisabetta
    Vitri, Benedetta
    Wells, Athol U.
    Nicol, Lisa M.
    Bianchi, Stephen
    Kular, Raman
    Liu, Hua Jian
    John, Alexander
    Barth, Sarah
    Wickremasinghe, Melissa
    ERJ OPEN RESEARCH, 2024, 10 (01)
  • [22] Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
    Schmid, Ulrike
    Weber, Benjamin
    Magnusson, Mats O.
    Freiwald, Matthias
    RESPIRATORY MEDICINE, 2021, 180
  • [23] Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
    Schmid, Ulrike
    Weber, Benjamin
    Magnusson, Mats O.
    Freiwald, Matthias
    BMC PULMONARY MEDICINE, 2021, 21 (01)
  • [24] Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
    Cottin, Vincent
    Richeldi, Luca
    Rosas, Ivan
    Otaola, Maria
    Song, Jin Woo
    Tomassetti, Sara
    Wijsenbeek, Marlies
    Schmitz, Manuela
    Coeck, Carl
    Stowasser, Susanne
    Schlenker-Herceg, Rozsa
    Kolb, Martin
    RESPIRATORY RESEARCH, 2021, 22 (01)
  • [25] Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
    Wollin, Lutz
    Distler, Joerg H. W.
    Redente, Elizabeth F.
    Riches, David W. H.
    Stowasser, Susanne
    Schlenker-Herceg, Rozsa
    Maher, Toby M.
    Kolb, Martin
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54 (03)
  • [26] THE INBUILD TRIAL OF NINTEDANIB IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES: SUBGROUP OF ASIAN PATIENTS
    Inoue, Yoshikazu
    Wells, Athol U.
    Song, Jin Woo
    Xu, Zuojun
    Kitamura, Hideya
    Suda, Takafumi
    Okamoto, Masaki
    Schlenker-Herceg, Rozsa
    Kolb, Martin
    Brown, Kevin K.
    Quaresma, Manuel
    Kolb, Martin
    Brown, Kevin K.
    RESPIROLOGY, 2019, 24 : 87 - 88
  • [27] Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial
    Matteson, Eric L.
    Kelly, Clive
    Distler, Joerg H. W.
    Hoffmann-Vold, Anna-Maria
    Seibold, James R.
    Mittoo, Shikha
    Dellaripa, Paul F.
    Aringer, Martin
    Pope, Janet
    Distler, Oliver
    James, Alexandra
    Schlenker-Herceg, Rozsa
    Stowasser, Susanne
    Quaresma, Manuel
    Flaherty, Kevin R.
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 (06) : 1039 - 1047
  • [28] Nintedanib for interstitial lung disease
    Thorley, Jennifer
    LANCET RHEUMATOLOGY, 2020, 2 (04): : E208 - E208
  • [29] Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial
    Inoue, Yoshikazu
    Wells, Athol U.
    Song, Jin Woo
    Xu, Zuojun
    Kitamura, Hideya
    Suda, Takafumi
    Okamoto, Masaki
    Mueller, Heiko
    Coeck, Carl
    Rohr, Klaus B.
    Kolb, Martin
    Brown, Kevin K.
    RESPIROLOGY, 2023, 28 (05) : 465 - 474
  • [30] The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases
    Matteson, Eric
    Kelly, Clive
    Distler, Joerg
    Mann-Vold, Anna Maria Hoff
    Seibold, James
    Mittoo, Shikha
    Distler, Oliver
    Goeldner, Rainer-Georg
    Schlenker-Herceg, Rozsa
    Stowasser, Susanne
    Quaresma, Manuel
    Flaherty, Kevin
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
12345